Viral and host factors associated with outcomes of hepatitis C virus infection (Review).
Hepatitis C virus (HCV) infection is a major health issue globally. Owing to the progress made in host genetics and HCV molecular virology, emerging data have suggested that the natural course and treatment response in patients with HCV infection are largely determined by complex host‑viral interactions. HCV genotype is the most important viral factor predicting the response to pegylated interferon‑α plus ribavirin therapy. The subtype of HCV genotype 1 is the key viral factor that predicts the efﬁcacy of direct‑acting antiviral therapy. HCV genome heterogeneity and baseline viral load are additionally associated with the treatment response. Multiple host genetic variants localized in genes associated with the immune response have been identified as predictors of spontaneous disease course and therapy outcome in chronic HCV. However, most findings from candidate gene association studies have not been proven universal for all investigated populations and independent studies. Previous findings in independent large genome wide association studies confirmed that interferon‑λ3 gene polymorphisms are associated with spontaneous clearance and treatment responsiveness. A polymorphism of the inosine triphosphatase gene has been identified as a protective factor against ribavirin‑induced anemia and dose reductions. Another genetic variant in the patatin‑like phospholipase domain containing 3 genes is associated with hepatic steatosis and fibrosis in patients with HCV. The present review focused on the identified viral and host factors associated with outcomes of patients with HCV, and assessed the involvement of viral and host genetics in the natural history and treatment outcomes of HCV infection. This will provide novel ideas concerning personalized prevention and individualized clinical management.
Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, Shapingba, Chongqing 400038, P.R. China.
Zehui
Z
Yan
Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, Shapingba, Chongqing 400038, P.R. China.
Yuming
Y
Wang
D000998:Antiviral Agents / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000378:metabolism; D055106:Genome-Wide Association Study; D016174:Hepacivirus / Q000235:genetics / Q000378:metabolism; D006526:Hepatitis C / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons; D007378:Interleukins / Q000235:genetics / Q000378:metabolism; D007694:Killer Cells, Natural / Q000276:immunology; D012254:Ribavirin / Q000627:therapeutic use; D019562:Viral Load; D014764:Viral Proteins / Q000378:metabolism*; D000095022:Interferon Lambda
D000998:Antiviral Agents; D060908:CTLA-4 Antigen; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D012254:Ribavirin; D014764:Viral Proteins; C556706:CTLA4 protein, human; C000624353:interferon-lambda, human; D000095022:Interferon Lambda